Substance / Medication

Magnesium carbonate

Overview

Active Ingredient
magnesium carbonate
RxNorm CUI
29155

Indications

Renacidin is indicated for dissolution of bladder calculi of the struvite or apatite variety by local intermittent irrigation through a urethral catheter or cystostomy tube as an alternative or adjunct to surgical procedures. Renacidin is also indicated for use as an intermittent irrigating solution to prevent encrustations of indwelling urethral catheters and cystostomy tubes.

Labeler: United-Guardian, Inc.Updated: 2019-12-17T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Renacidin is contraindicated in the presence of demonstrable urinary tract extravasation.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
[The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
Zwiech Rafał, Dryja Przemysław, Łacina Dominik et al. · Wiad Lek · 2011
PMID: 21812357RCT
Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial.
Tzanakis Ioannis P, Papadaki Antonia N, Wei Mingxin et al. · Int Urol Nephrol · 2008
PMID: 18193489RCTFull text (PMC)
Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
Spiegel David M, Farmer Beverly, Smits Gerard et al. · J Ren Nutr · 2007
PMID: 17971314RCT
The effect of replacing aluminium hydroxide with calcium acetate/magnesium carbonate on serum phosphorus control in haemodialysis patients.
Arroyo David, Panizo Nayara, Abad Soraya et al. · Nefrologia · 2014
PMID: 24658194Observational
Effect of calcium acetate/magnesium carbonate in the treatment of hyperphosphataemia in dialysis patients in real clinical practice. One year follow up.
de Francisco Angel L M, Belmar Lara, Piñera Celestino et al. · Nefrologia · 2014
PMID: 25259817Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Magnesium carbonate (substance)
SNOMED CT
387401007
UMLS CUI
C0065517
RxNorm CUI
29155
Labeler
United-Guardian, Inc.

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.